The glacial development of Fate’s anti-CD19 Car-NK therapy FT596 could yield real data at last.
The company is now in the clinic, claiming to have cleared one of the biggest hurdles blocking development of an NK cell therapy.
Nantkwest claims efficacy with its most advanced NK cell therapy but, as ever with Patrick Soon-Shiong companies, it’s complicated.
A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.
Sanofi goes all in on Kiadis's natural killer cell projects, gained through an all-stock deal in 2019.
Shortly after canning its lead and acquiring the NK cell company Cytosen, Kiadis flips part of the tech to Sanofi.